Decode the Environment Variation of Targeted Aldosterone Inducer and siLencer (DETAIL)

September 30, 2026 updated by: Nathaphong Dejthida, DejthidaNathaphong

Clinical outcome to identify and analyze the epigenetic, phenotypic, protein variation, metabolites of CYP450 Family 11 Subfamily B, both 1 and 2, human-associated aldosterone protein release, and signaling inhibitory pathways post-aldosterone-mineralocorticoid interaction.

We will include clinical studies (RCTs, cohort, case-control/series/report) from fresh human specimens. We will exclude animal studies, studies generated from cell culture, and aldosterone synthesis.

To systematically review and synthesize the literature on the main 2 questions Question 1: Which environment induces CYP11B1 or CYP11B2 activation causing hyperaldosteronemia in hypertension patients? Question 2: Which intracellular signal silences aldosterone-MR activity? For Individual Participant Data Meta-analysis, data will be extracted from final analysis articles from the framework of the data selection process only; the effect measurement and multi-variable model meta-analysis will be performed.

Primary Objective1: to identify CYP450 Family 11 Subfamily B and Aldosterone in hypertension patients following; By structure ● Evidence confirms Epigenetic profile of CYP450 Family 11 Subfamily B, Aldosterone, Signal in hypertension patients, both random and treated from any DNA sequencing method Protein synthesis evidence of aldosterone protein induces hypertension from Western blot or LC-MS By function Metabolomic profile: the substrate or product refers to aldosterone interaction causing end-organ cell line dysfunction or impaired structure.

Inhibitory signaling profiling of hypertension patients compared to non-hypertension patients, which negatively feedback to CYP450 Family 11 Subfamily B or Aldosterone

Secondary Objective 2:

Sub-group analysis effect measurement following;

  • Proposed mechanisms, biological markers, or pathways that contribute to failure to regulate aldosteronemia
  • Treatment-related permanent normotensive post-hyperaldosteronemia. Primary Objective 2: Identify possible intracellular signal inhibit aldosterone action
  • Analyze possible mechanisms of signal that are silent aldosterone-MR activity
  • Differentiation of free aldosterone and attached aldosterone

Secondary Objective 2:

● Sensitivity and specificity of outcomes of hypertension patients who underwent estimate substrate associated aldosterone circulation Plasma CYP450 Family 11 Subfamily B Urine CYP450 Family 11 Subfamily B Plasma Aldosterone (active form) Plasma Aldosterone (metabolite form) Urine Aldosterone

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Primary Objective1: to identify CYP450 Family 11 Subfamily B and Aldosterone in hypertension patients following; By structure ● Evidence confirms Epigenetic profile of CYP450 Family 11 Subfamily B, Aldosterone, Signal in hypertension patients, both random and treated from any DNA sequencing method Protein synthesis evidence of aldosterone protein induces hypertension from Western blot or LC-MS By function Metabolomic profile: the substrate or product refers to aldosterone interaction causing end-organ cell line dysfunction or impaired structure.

Inhibitory signaling profiling of hypertension patients compared to non-hypertension patients, which negatively feedback to CYP450 Family 11 Subfamily B or Aldosterone

Secondary Objective 2:

Sub-group analysis effect measurement following;

  • Proposed mechanisms, biological markers, or pathways that contribute to failure to regulate aldosteronemia
  • Treatment-related permanent normotensive post-hyperaldosteronemia. Primary Objective 2: Identify possible intracellular signal inhibit aldosterone action
  • Analyze possible mechanisms of signal that are silent aldosterone-MR activity
  • Differentiation of free aldosterone and attached aldosterone

Secondary Objective 2:

● Sensitivity and specificity of outcomes of hypertension patients who underwent estimate substrate associated aldosterone circulation Plasma CYP450 Family 11 Subfamily B Urine CYP450 Family 11 Subfamily B Plasma Aldosterone (active form) Plasma Aldosterone (metabolite form) Urine Aldosterone Axin-CK1-GSK3-APC-Beta-catenin complex

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Nathaphong Dejthida, Medical Degree
  • Phone Number: +66819220662
  • Email: bnnatto@gmail.com

Study Locations

  • Thailand
    • Bangkok
      • Vadhana, Bangkok, Thailand, 10110
        • Investigation Center
        • Contact:
          • Nathaphong Dejthida, Medical Degree
          • Phone Number: +66819220662
          • Email: bnnatto@gmail.com
        • Contact:
        • Principal Investigator:
          • Nathaphong Dejthida, Medical Degree

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Human birth in all sex chromosomes; evidence of systemic arterial hypertension, both treated and untreated.
  • Evidence of living with owned systemic/arterial hypertension by one of the following;
  • Quantitative: Blood pressure number higher than the normal range by each protocol in mmHg unit in any arm of study.
  • Qualitative: Clarify whether both retrospective, observational, or intervention study of blood pressure, and clearly clarify the number of hypertension participants in the article.

Exclusion Criteria:

  • Under 18 years old
  • Specimens of studies not from humans or human specimens but not from an actual living hypertension patient, such as cell culture, in vitro synthesis from laboratory synthesis
  • No evidence of hypertension in the main study
  • Study of imaging confirms adrenal tumor in all types of histopathology results.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hypertensive Hyperaldosteronemia
Diagnostic test: Aldosterone circulation

Evidence of synthesis of aldosterone and/or degradation of inactive forms of aldosterone, which focuses on

  • CYP450 Family 11 Subfamily B
  • Aldosterone protein
  • Beta-catenin
  • Axin-CK1-GSK3-APC complex
Drug: Medication

Medical treatment that interferes with free aldosterone levels and reports systolic blood pressure deviation

Procedure: Operation

The non-medical intervention includes MIS, Open surgery, and intravascular guide treatment aim to treat hypetension and lower aldosterone level.
Active Comparator: Hypertensive normoaldosteronemia
Diagnostic test: Aldosterone circulation

Evidence of synthesis of aldosterone and/or degradation of inactive forms of aldosterone, which focuses on

  • CYP450 Family 11 Subfamily B
  • Aldosterone protein
  • Beta-catenin
  • Axin-CK1-GSK3-APC complex
Drug: Medication

Medical treatment that interferes with free aldosterone levels and reports systolic blood pressure deviation

Procedure: Operation

The non-medical intervention includes MIS, Open surgery, and intravascular guide treatment aim to treat hypetension and lower aldosterone level.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Aldosterone circulation profile
Time Frame: 12 months

The result, both qualitative and quantitative, from aldosterone synthesis to degradation and elimination via urine.
12 months
Aldoseterone synthesis profile
Time Frame: 12 months

Focus on both quantitative and qualitative evidence of aldosterone, CYP11B1, andand CYP11B2 protein
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Degradation Profile
Time Frame: 12 months

Focus on the ratio of degradation activity of the inactive form of aldosterone and the inhibitory competitor inhibits the cell product from the aldosterone-mineralocorticoid receptor. Axin-CK1-GSK3-APC complex profile is indicated
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

DejthidaNathaphong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 10, 2026

Primary Completion (Estimated)

February 10, 2027

Study Completion (Estimated)

February 5, 2028

Study Registration Dates

First Submitted

July 28, 2026

First Submitted That Met QC Criteria

July 31, 2026

First Posted (Actual)

August 6, 2026

Study Record Updates

Last Update Posted (Actual)

October 1, 2026

Last Update Submitted That Met QC Criteria

September 30, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NDejthida

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The recruitment is published data already

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe